(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 14.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.01%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.91%.
Codexis's revenue in 2026 is $77,679,000.On average, 9 Wall Street analysts forecast CDXS's revenue for 2026 to be $8,254,982,589, with the lowest CDXS revenue forecast at $7,834,042,428, and the highest CDXS revenue forecast at $8,566,088,467. On average, 8 Wall Street analysts forecast CDXS's revenue for 2027 to be $9,766,709,675, with the lowest CDXS revenue forecast at $8,671,104,496, and the highest CDXS revenue forecast at $12,521,984,228.
In 2028, CDXS is forecast to generate $13,092,509,263 in revenue, with the lowest revenue forecast at $9,905,234,467 and the highest revenue forecast at $16,390,822,905.